These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 19157532)

  • 21. Remission in early rheumatoid arthritis.
    Ma MH; Scott IC; Kingsley GH; Scott DL
    J Rheumatol; 2010 Jul; 37(7):1444-53. PubMed ID: 20516031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 26. [Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis].
    Imagama T; Taguchi T
    Nihon Rinsho; 2013 Jul; 71(7):1209-13. PubMed ID: 23961668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis.
    Sandoo A; Panoulas VF; Toms TE; Smith JP; Stavropoulos-Kalinoglou A; Metsios GS; Gasparyan AY; Carroll D; Veldhuijzen van Zanten JJ; Kitas GD
    J Hum Hypertens; 2011 Nov; 25(11):699-702. PubMed ID: 21525886
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Verhoeven AC; Boers M
    Ned Tijdschr Geneeskd; 2001 Nov; 145(47):2294-5. PubMed ID: 11760611
    [No Abstract]   [Full Text] [Related]  

  • 29. [TNF-inhibitors slow down joint destruction in rheumatoid arthritis. No cure, but dramatic relief of symptoms].
    Wollheim FA
    Lakartidningen; 2001 May; 98(21):2560-2. PubMed ID: 11433990
    [No Abstract]   [Full Text] [Related]  

  • 30. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis.
    Chen SJ; Lin GJ; Chen JW; Wang KC; Tien CH; Hu CF; Chang CN; Hsu WF; Fan HC; Sytwu HK
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seropositive erosive rheumatoid arthritis (RA).
    Matthews C; Fitzgerald O
    Rheumatology (Oxford); 2006 Sep; 45(9):1100. PubMed ID: 16943373
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [TNF-alpha antagonist in rheumatoid arthritis. Joint destruction can be controlled].
    MMW Fortschr Med; 2003 Oct; 145(41):46. PubMed ID: 14655484
    [No Abstract]   [Full Text] [Related]  

  • 37. Rheumatoid arthritis: an overview of new and emerging therapies.
    Doan T; Massarotti E
    J Clin Pharmacol; 2005 Jul; 45(7):751-62. PubMed ID: 15951465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 39. Adalimumab therapy in rheumatoid arthritis.
    Keystone E; Haraoui B
    Rheum Dis Clin North Am; 2004 May; 30(2):349-64, vii. PubMed ID: 15172045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
    Bobbio-Pallavicini F; Caporali R; Bugatti S; Montecucco C
    J Rheumatol; 2008 Oct; 35(10):1903-5. PubMed ID: 18843754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.